All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Wavelength-Pharmaceuticals-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Orexo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Positive Results from Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations for Opioid Overdose Reversal

Contact the Supplier

Lead Product(s): Nalmefene

Therapeutic Area: Psychiatry/Psychology Product Name: OX125

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

The study was a cross-over, comparative bioavailability study in healthy volunteers to assess nalmefene absorption from three development formulations of OX125, Orexo's wholly-owned nasal nalmefene product, compared to a nalmefene intramuscular injection.